Vigonvita Life Sciences Co Ltd
Company Profile
Business description
Vigonvita Life Sciences Co Ltd biopharmaceutical company. It is focused on innovation driven biopharmaceutical development, with a strategic emphasis on addressing unmet clinical needs in the treatment of neuropsychiatric, infectious, and andrological diseases. The company's core Products include LV232, anti-depression drug candidate, VV913: a novel investigational drug candidate for premature ejaculation and, VV116: an oral nucleoside analog with broad-spectrum antiviral potential. The company's operations are located in the PRC and Uzbekistan. Revenue is generated from the out-licensing and the sales of its pharmaceutical products.
Contact
No. 108, Yuxin Road
8th Floor, Building A
Suzhou Industrial Park District
Suzhou215123
CHNT: +86 51262898861
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
315
Stocks News & Analysis
stocks
Ask the analyst: Where does GYG stand following its US exit?
stocks
Chart of the Week: The long term headwinds facing copper shares
stocks
Australia’s oldest REIT undervalued
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,915.20 | 6.50 | -0.07% |
| CAC 40 | 8,337.29 | 66.70 | -0.79% |
| DAX 40 | 25,040.28 | 44.47 | 0.18% |
| Dow JONES (US) | 52,305.24 | 13.96 | -0.03% |
| FTSE 100 | 10,478.34 | 18.78 | -0.18% |
| HKSE | 23,050.39 | 169.37 | 0.74% |
| NASDAQ | 26,040.03 | 173.69 | -0.66% |
| Nikkei 225 | 69,591.75 | 883.21 | -1.25% |
| NZX 50 Index | 13,522.05 | 88.45 | -0.65% |
| S&P 500 | 7,483.23 | 16.13 | -0.22% |
| S&P/ASX 200 | 8,710.10 | 0.50 | -0.01% |
| SSE Composite Index | 4,083.73 | 28.72 | -0.70% |